Selective RET specific-tyrosine kinase inhibitors (RET-TKIs) Pralsetinib and Selpercatinib have been approved by the US Food and Drug Administration to treat RET fusion-positive NSCLC, showing highly selective tyrosine kinase inhibition. The gene discussed is RET; the disease is non-small cell lung carcinoma.